![]() Colchicine : New recommendations on the use of colchicine in hospitalized and ambulatory persons with COVID-19.Īdditionally, three new narrative sections have been developed:.Ivermectin: Revised recommendations on the use of ivermectin in hospitalized and ambulatory persons with COVID-19.They were provided here for immediate use and have now been integrated into the website as part of Version 10.0.0. The following sections were added/revised based on newly available literature and/or approvals. Version 10.0.1 has been released and includes minor corrections to Table 22 and Table 35. This update been endorsed by the Society for Healthcare Epidemiology of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. ![]() ![]() They were provided here for immediate use and were integrated into the website as part of Version 10.1.0 The following sections have been updated based on newly available literature and approvals. Ivermectin: This section has been updated based on newly added literature.Inhaled Corticosteroids: This recommendation on the use of inhaled corticosteroids among ambulatory patients with mild-to-moderate COVID-19 has been revised.Version 10.1.0 has been released and includes the following: Version 10.1.1 has been released and includes updates to Figure 7, Figure 8, and Figure 9. This update has been endorsed by the Society for Healthcare Epidemiology of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Neutralizing Antibodies for Treatment: This recommendation was retired and replaced with a statement mentioning that the US FDA withdrew Emergency Use Authorization for bebtelovimab, the one anti-SARS CoV-2 neutralizing antibody product that had retained in vitro activity against most previously circulating SARS-CoV-2 variants, leaving no available neutralizing antibody product in the United Sates for treatment of COVID-19.Neutralizing Antibodies for Post-Exposure Prophylaxis: This recommendation was retired and replaced with a statement mentioning in vitro resistance of casirivimab/imdevimab to circulating strains of COVID-19 in the US. ![]() The agent has an Emergency Use Authorization by the US FDA and may be used in other parts of the world where the circulating COVID-19 variants may still be susceptible to it.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |